The deal size was increased to $750M in common stock from $600M in common stock. JPMorgan, TD Cowen, Goldman Sachs and Guggenheim acted as joint book running managers for the offering.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $87 from $82 at Guggenheim
- Revolution Medicines price target raised to $71 from $63 at JPMorgan
- Revolution Medicines announces $600M common stock offering
- Revolution Medicines price target raised to $80 from $70 at Stifel
- Revolution Medicines provides updates from RAS(ON) inhibitor combo studies